Engflag

Pyrantrin

Quick links to important sections

Pyrantrin

Pyrantrin_CS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pyrantrin

Property Description
Active ingredient Pyrantel Embonate
Form Oral Suspension, Syrup, Tablets
Pharmacological class Anthelmintic (Antiparasitic)
General purpose Clearance of intestinal worm infections
Origin Synthetic, Pyrimidine Derivative

Pyrantrin: Definition, Pharmacological Class, and General Purpose

Pyrantrin is a specific trade name for a medication whose active compound is Pyrantel Embonate, which is fundamentally classified as an anthelmintic agent. This drug belongs to the class of antiparasitic medicines, specifically functioning as an antinematodal agent targeting roundworms and other helminths. Its primary therapeutic purpose is the clearance of these intestinal worm infections from the host organism.

The base compound, Pyrantel, is a synthetic pyrimidine derivative whose importance is recognized by its inclusion on the World Health Organization Model List of Essential Medicines. Pyrantrin is specifically known for its presentation as a liquid Oral Suspension or Syrup, often positioning it as a preferred choice for the pediatric target audience and whole-household treatment scenarios.

Active Ingredient and Available Dosage Forms

The core active ingredient is Pyrantel Embonate, which is formulated for oral administration. The medication is available in several dosage forms, including the liquid Oral Suspension or Syrup, and sometimes as solid Tablets or Chewable Tablets. The compound's low solubility is a key feature, as it minimizes systemic absorption into the bloodstream, allowing it to concentrate its effect locally in the intestine.

How Pyrantrin Works at a Conceptual Level

Pyrantrin’s high-level mechanism of effect involves its function as a depolarizing neuromuscular blocking agent specific to the worms. This action induces spastic paralysis in the susceptible parasites, leading to their inability to anchor to the intestinal wall. This paralyzing effect is crucial to the drug’s general purpose, as it allows the body's natural intestinal movement, peristalsis, to expel the inert parasites, ensuring efficient infection clearance.

Regulatory References

  1. World Health Organization's (WHO) Model List of Essential Medicines
  2. WHO

What side effects are possible with Pyrantrin?

Pyrantrin’s (Pyrantel Embonate) official safety profile is primarily defined by documented adverse reactions affecting the digestive and nervous systems, consistent with regulatory classifications from health authorities like the FDA and EMA.

Documented Adverse Reactions

The most frequently documented effects often fall under the Less Common classification in official U.S. regulatory summaries. These effects are generally grouped by the body system affected:

System-Organ Class Examples of Documented Reactions
Gastrointestinal Abdominal cramps or pain, nausea, vomiting, diarrhea, loss of appetite (anorexia), tenesmus.
Nervous System Headache, dizziness, drowsiness, trouble in sleeping (insomnia).
Hepatobiliary Transient increases in liver enzyme values.

Safety Constraints and Special Populations

Official labeling specifies several constraints and populations requiring particular safety consideration:

  • Serious Adverse Reactions: The potential for hypersensitivity or allergic reactions is documented, representing a rare but clinically significant adverse event.
  • Pediatric Limitations: Use is officially restricted in children under 2 years of age or those weighing less than 25 pounds, unless under medical direction, as efficacy and safety are not established for this group.
  • Hepatic Impairment: Individuals with a history of liver disease should not use the medication unless advised by a healthcare professional.
  • Contraindications: The medicine is contraindicated in patients with known hypersensitivity to its components and in those with pre-existing intestinal obstruction.
  • Drug Interaction Note: Co-administration with piperazine should be avoided due to the documented risk of pharmacodynamic antagonism, which may reduce the efficacy of both treatments.

These official statements regarding adverse effects, specific patient groups, and contraindications define the complete regulatory safety structure of the medicine.

Overdose and Emergency Response

The official regulatory profile for Pyrantrin (Pyrantel Embonate) overdose is primarily defined by the drug's low systemic absorption. This results in low plasma concentrations even after a significant overdose, which minimizes the potential for severe systemic toxicity. Consequently, the severity of overdose is generally classified in official documents as leading to mild, transient symptoms.

The documented clinical manifestations of overdose are generally mild and affect the gastrointestinal and central nervous systems. Regulator-listed symptoms explicitly include nausea, vomiting, diarrhea, abdominal cramps, headache, and dizziness. Furthermore, official prescribing information notes that a temporary, slight increase in liver enzymes may occur.

A central regulatory instruction is that no specific antidote is known for Pyrantrin overdose, and management focuses entirely on symptomatic and supportive treatment. Due to this constraint, government labeling mandates that a person must seek immediate medical attention or contact a Poison Control Center right away in the event of any suspected overdose or accidental ingestion. Population-specific guidance advises caution for patients with impaired liver function due to the potential for minor, transient enzyme changes.

Therapeutic Uses of Pyrantrin

What Pyrantrin Treats: Main Uses and Benefits

Pyrantrin is commonly used in the symptomatic management of conditions presenting with systemic or localized discomfort caused by specific intestinal roundworms, including pinworms (Enterobius vermicularis), roundworms (Ascaris lumbricoides), and hookworms (Necator americanus or Ancylostoma duodenale). Its application is relevant in conditions characterized by periods of heightened symptoms that involve specific intestinal parasites.

Symptom Management and Easing Discomfort

The medication is relevant for easing symptomatic discomfort when the parasitic presence causes heightened patient distress. It addresses symptoms related to inflammatory or irritative states, such as the severe, often nocturnal, perianal itching characteristic of pinworm infections. It also may assist in easing discomfort symptoms related to physical discomfort, such as abdominal cramping. Pyrantrin is commonly used across all affected age groups, including pediatric patients and adults. It is also applied in clinical settings for the management of close contacts of an infected individual to support broader infection control efforts.

“Supportive relief may help patients cope more steadily with symptom fluctuations during difficult episodes and helps maintain a sense of stability when symptoms are more noticeable.”

This supports general well-being during symptomatic phases and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Pruritus Ani

  • Quick Fact: Relief for Pruritus Ani (Anal Itching) – Pyrantrin is relevant for managing symptoms that interfere with daily comfort, focusing on the acute discomfort associated with pinworm infestations.

Regulatory References

  1. NIH MedlinePlus information on Pyrantel

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Pyrantrin — Official Regulatory Information

This profile outlines the population eligibility and restriction rules for Pyrantrin (Pyrantel Embonate) as defined in government regulatory labeling.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children 2 years of age and older are approved for use.
Populations for whom use is not recommended Use is not recommended for children less than 2 years of age or those weighing less than 25 pounds unless administered by a physician.
Contraindicated populations/conditions Use is strictly contraindicated in individuals with known hypersensitivity to pyrantel or any component.
Age-related eligibility rules Approval is established for individuals 2 years and older; safety and efficacy are not established in the younger age group.
Condition-specific eligibility rules Individuals with liver disease must not take this product unless directed by a doctor. Use is generally cautioned in patients with anemia or malnutrition.
Pregnancy and lactation eligibility status Pregnant women must not take the product unless directed by a doctor. Use during lactation is generally classified as unknown due to insufficient data.

Connection to the overall eligibility profile: Regulatory documentation defines who can and cannot use the medicine by establishing a clear minimum age of eligibility (2 years old) and restricting use based on specific physiological states (pregnancy, lactation) and pre-existing conditions like hepatic disease, all of which require physician guidance outside of standard labeled use.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Pyrantrin

Interaction Scope

  • Medicinal product categories with documented interactions: Other anthelmintic agents, xanthine derivatives, and substances with central nervous system (CNS) effects.
  • Specific interacting medicines (if explicitly listed): Piperazine.
  • Mechanistic basis of interactions (only if stated in label): Pharmacodynamic antagonism (for Piperazine) and potential additive CNS effects.
  • Timing-based interaction rules (if applicable): None documented. The drug may be taken with or without food.
  • Population-specific interaction notes (if applicable): No statements documented that specify a change in interaction severity based on patient population.
  • Interaction-related restrictions: Prohibition against co-administration with Piperazine.

Interaction Classifications (High-level)

  • Interaction severity classification (as defined in official documents): Formal Contraindication (for Piperazine combination).
  • Regulatory basis (EMA / FDA / etc.): Based on official government prescribing information.
  • Interaction-context constraints (as defined in official documents): Consumption of alcohol may increase the risk of CNS effects. Prohibition against co-administration with Piperazine.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Piperazine is formally contraindicated due to pharmacodynamic antagonism, which may reduce the therapeutic efficacy of both medicines.
  • A minor interaction is documented with Theophylline, where co-administration may increase the plasma concentrations of Theophylline.
  • There is no documented interaction with food, milk, or fruit juice; the product is approved for administration with or without meals.
  • The product may cause an additive CNS effect with substances like alcohol, which can increase the risk of dizziness or drowsiness.

Connection to the overall interaction profile (2–4 sentences):

The official regulatory profile for Pyrantrin is primarily defined by the specific, mandatory restriction involving Piperazine, citing pharmacodynamic conflict. The structure is also marked by an explicit absence of interaction with common consumables, dictating administration flexibility, and includes a cautionary note regarding the potential for additive central nervous system effects with certain co-administered substances.

Mechanism of Action

The mechanism of action for Pyrantrin, whose active compound is Pyrantel Embonate, is focused entirely on the neuromuscular system of susceptible parasitic worms. The molecule acts as an agonist on specialized Nicotinic Acetylcholine Receptors (nAChRs) found on the parasite's muscle cells. This highly selective interaction causes a persistent and uncontrolled activation of the receptor site, overwhelming the worm's cholinergic neuromuscular system.

This sustained excitation initiates a depolarizing neuromuscular blockade, locking the worm’s somatic musculature in a state of spastic paralysis (rigid contraction). This physiological consequence eliminates the worm's ability to maintain anchorage within the intestinal lumen. The inert parasite is then passively expelled from the host's body by the normal, mechanical forces of peristalsis. This mechanism is constrained by its receptor specificity, rendering it ineffective against parasites, like tapeworms, that lack the susceptible nAChR subtypes.

Dosage and Administration Information

How to Use Pyrantrin

Pyrantrin, which contains the active ingredient Pyrantel Pamoate, is administered strictly through the oral route for its intended anthelmintic purpose. The medication is available as an Oral Suspension (or Syrup) and as Tablets or Chewable Tablets, formulated to facilitate consumption across different age groups.

Official Dosing and Administration Protocol

The dosage is standardized and based on the patient's body weight, utilizing 11 mg of pyrantel base per kilogram of body weight (or 5 mg/lb). The total amount administered as a single dose must not exceed 1 gram of pyrantel base. This weight-based measurement ensures the proper concentration reaches the target area within the intestine.

Indication Standard Regimen Frequency / Duration
Roundworm (A. lumbricoides) 11 mg/kg single dose Once
Pinworm (E. vermicularis) 11 mg/kg single dose Once, repeated in 2 weeks
Hookworm (N. americanus)* 11 mg/kg per dose Once daily for 3 consecutive days

Administration Contexts

Administration is flexible: the dose may be taken at any time of day and is effective whether administered with or without food. If using the liquid suspension, the container must be shaken well before the dose is measured using a calibrated device. The liquid may be taken alone or mixed with a vehicle like milk or fruit juice. The official instruction for pinworm infections often involves treating the entire household simultaneously to mitigate the potential for re-infection.

Population-Specific Rules

Use is generally confined to children 2 years of age and older (or those weighing 25 lbs or more) unless explicit instruction is provided by a physician. The official protocol states that laxatives are not required prior to, during, or after treatment.

Recent Clinical Evidence

Research evidence / Overview of studies for Pyrantrin

This section provides an overview of the clinical research and study designs that regulators have reviewed for Pyrantrin (Pyrantel Embonate). This information focuses on what was studied and what the research evidence indicates so far, without offering advice or clinical recommendations.

Evidence for use in Roundworm Infections (Ascaris lumbricoides)

Research for roundworm infection was evaluated in Randomized Controlled Trials (RCTs) and systematic reviews. These trials primarily measured two key outcomes: the Parasitological Status Rate, which evaluated the status of parasite eggs in stool samples after administration, and the Faecal Egg Count Status (ERR), which monitored the status of egg burden. Study populations mainly included school-aged children.

Studies consistently described measurements related to the status of parasite eggs in stool samples following administration. Reports documented patterns related to the monitored parasite presence. The evidence base provides limited insight into long-term infection recurrence rates following initial observed change.

Evidence for use in Pinworm Infections (Enterobius vermicularis)

The evidence for pinworm infection was studied for its parasitological status using methods like the Scotch-tape test. Research also explored patient-reported outcomes describing perceived discomfort, such as monitoring perianal itching. These trials included children and adults.

Findings describe patterns observed in the studies where a scheduled re-treatment protocol was used, reflecting the parasite's life cycle. The required use of repeat administration protocols in these trials means that data for single-dose assessment remains limited against this specific life cycle.

Evidence for use in Hookworm Infections (Necator americanus or Ancylostoma duodenale)

Research for hookworm infection was evaluated in RCTs, Field Trials, and systematic reviews. The primary outcomes studied were the Parasitological Status Rates (CRs) and the Faecal Egg Count Status (ERR). Studies reported patterns related to changes in parasitological status, but the documented status rates varied substantially across different geographic regions.

Limited comparative evidence is available for certain clinical scenarios. The observed variability indicates limitations in applying findings across all settings.

What is still uncertain about Pyrantrin

Data for long-term effects are not fully established, and evidence for recurrence rates is limited. Additionally, evidence quality varies across studies, particularly for the hookworm indication where findings were mixed across different geographic regions. Subgroup findings are uncertain when moving beyond the core populations of school-aged children and general adults.

Frequently Asked Questions (FAQ)

Common questions about Pyrantrin (FAQ)

Q: How fast does Pyrantrin start working after you take it?

A: Pyrantrin's mechanism is focused on paralyzing the susceptible worms in the intestine. Official product information indicates that the active compound reaches its peak concentration within the body approximately one to three hours after the dose is taken. However, the exact time it takes for the entire infection to clear and symptoms to fully resolve can vary by individual.

Q: Does alcohol interact negatively with Pyrantrin?

A: Official product information notes an interaction with alcohol. Co-administering Pyrantrin with alcohol may result in an additive central nervous system (CNS) effect. This can increase the likelihood of experiencing side effects such as dizziness or drowsiness.

Q: Can taking Pyrantrin cause changes in my bowel movements?

A: Changes in bowel movements may occur. Documented adverse reactions associated with Pyrantrin include gastrointestinal effects such as abdominal cramps or pain, diarrhea, and tenesmus (straining). This is partly due to the drug's intended action of helping the body expel the paralyzed parasites from the digestive tract.

Q: What happens if I take Pyrantrin close to bedtime?

A: Pyrantrin is approved to be taken at any time of day, as it is effective with or without food. However, official information lists side effects that affect the nervous system, including dizziness and insomnia (trouble sleeping). It is important to be aware of the possibility of these potential effects, as they may occur regardless of the time the dose is taken.

Q: How long does Pyrantrin stay in your system?

A: The active compound in Pyrantrin has low solubility, meaning it is minimally absorbed into the bloodstream and acts mainly within the intestines. Regulatory summaries do not precisely define the duration of the drug's active effect or when it is completely eliminated from the body.

Q: Is it normal to still have symptoms a day after taking Pyrantrin?

A: If symptoms or visible signs of infection, such as parasites, persist more than a day after taking the medication, it is important to contact a healthcare provider for follow-up. While the drug starts working quickly, the time it takes for the infection to fully clear can vary.

Q: Why do you sometimes have to take Pyrantrin more than once?

A: For certain infections, like pinworm, the official dosing regimen often requires a repeat dose approximately two weeks after the initial administration. This structured two-part treatment is necessary to target the parasite's life cycle and treat any eggs that may have hatched after the first dose was given.

Q: Are there any specific foods to avoid when taking Pyrantrin?

A: Official product labeling does not indicate any necessary restrictions regarding food. Pyrantrin is approved for flexible administration, meaning it can be taken with or without food, or mixed with a vehicle like milk or fruit juice.

Q: Why do doctors suggest treating the whole family with Pyrantrin?

A: For pinworm infections, the official guidance often instructs the simultaneous treatment of all members in the household. This is a preventative measure designed to mitigate the high potential for immediate re-infection or cross-infection among family members.

Q: Is Pyrantrin available in liquid form for kids?

A: Yes, Pyrantrin is manufactured in several forms, including liquid Oral Suspension and Syrup. These liquid formulations are commonly used for children or for individuals who have difficulty swallowing solid tablets.

Q: What should I do if I forget to take a dose of Pyrantrin?

A: For single-dose treatments, the general regulatory guidance is to take the dose as soon as it is remembered. For all dosing questions, patients should follow the specific directions provided by their pharmacist or healthcare provider.

Q: Are there long-term side effects from using Pyrantrin?

A: Most people use Pyrantrin for short-term treatment of a single infection. Regulatory overviews of the research acknowledge that data on the full range of potential long-term effects following extended use are not fully established.

Q: Does Pyrantrin affect my ability to drive or operate machinery?

A: Due to the potential for side effects such as dizziness and drowsiness, official information advises caution. It is important that individuals who experience these effects do not drive a vehicle or operate complex machinery until these effects have completely passed.

Q: What are the signs that Pyrantrin is actually working?

A: Clinical trials for Pyrantrin primarily monitor the Parasitological Status Rate, which tracks the reduction or clearance of parasite eggs in stool samples. Patient-reported outcomes related to perceived discomfort, such as a reduction in perianal itching, are also monitored.

Q: Is it possible to be allergic to Pyrantrin?

A: Yes, it is possible. Regulatory documentation states that Pyrantrin is strictly contraindicated, or forbidden, for use in individuals who have a known hypersensitivity or allergic reaction to the active ingredient, pyrantel, or any other component in the medicine.

Q: Is it normal to see worms in the stool after taking Pyrantrin?

A: Pyrantrin's primary action is to cause spastic paralysis in the susceptible worms. This paralysis causes the worms to lose their grip on the intestinal wall, allowing them to be passively expelled from the body via normal intestinal movement. Seeing the paralyzed, inert parasites is consistent with the drug's mechanism.

Q: How soon can I take Pyrantrin again if the infection comes back?

A: Official guidance states that re-treatment should not occur unless it is specifically directed by a healthcare professional. If you notice signs that the infection has returned or symptoms persist after the initial treatment course, contact a healthcare provider for further guidance.

Q: What are the signs of an overdose of Pyrantrin?

A: Official product warnings emphasize the importance of contacting a local Poison Control Center or seeking professional emergency assistance immediately in the event of any suspected accidental overdose.

Q: Why is hygiene so important when using Pyrantrin?

A: Hygiene is strongly emphasized in conjunction with treatment to help prevent re-infection. Simple measures, such as frequent and thorough handwashing (especially before eating and after using the bathroom), are recommended as part of the total management plan.

Q: Can Pyrantrin cause an itchy feeling?

A: While pruritus (itching) is not listed among the main nervous or gastrointestinal side effects, clinical research on pinworm infection has monitored patient-reported outcomes like perianal itching. This discomfort can be related either to the original infection or the body's reaction to the treatment.

Q: Are there any studies on Pyrantrin use in infants?

A: The safety and effectiveness of Pyrantrin have not been established for use in children under 2 years of age or those weighing less than 25 pounds. This means that the medicine is generally restricted for use in this young age group, which includes most infants.

How should Pyrantrin be stored and disposed of?

How to Store and Dispose of Pyrantrin

The storage and disposal of Pyrantrin (Pyrantel Pamoate) must adhere strictly to regulatory requirements to ensure product stability and safety.

Storage Requirements

Pyrantrin must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must not be frozen and should be kept away from excess moisture and heat. It must be maintained in its original container and the cap must remain tightly closed. For child safety, the medicine is required to be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Pyrantrin must be disposed of properly according to official guidelines. Disposal should utilize a medicine take-back program when available. If no take-back option exists, the medicine should be mixed with an undesirable substance, placed into a sealed container, and discarded in the household trash. It must not be poured down a sink or flushed down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Pyrantrin found in:

A-Z Index: